Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
for Advanced Lung Non-Small Cell Carcinoma
Drug: Osimertinib
345 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT03191149·Phase 2·Recruiting